Internal Medicine, Hematology & Oncology · Birmingham, AL
NPI
1538192570
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
100 Pilot Medical Drive, Suite 175
Birmingham, AL, 35235
Phone (205) 856-8488
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
152,810 services
Medicare patients, 2024
368
Average age 75
Drug cost, 2024
$7.0M
3,239 prescriptions
Company payments, 2025
$9,059
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shailendra Lakhanpal was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 13,060 times for 12 patients. In total Shailendra Lakhanpal billed 152,810 services in 106 codes, and Medicare paid $2.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-03-10.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 13,060 | 12 | $2.35 | $31K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 12,750 | 13 | $0.89 | $11K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 9,690 | 13 | $0.29 | $2,855 |
| J0897 Injection, denosumab, 1 mg | Office | 4,080 | 17 | $20.49 | $84K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,600 | 20 | $16.32 | $42K |
| 85025 Blood Count | Office | 947 | 247 | $7.54 | $7,144 |
| 36415 Venipuncture Blood Collection | Office | 733 | 226 | $8.61 | $6,309 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 728 | 18 | $0.08 | $61.29 |
| 99214 Office E&M - Established | Office | 455 | 154 | $87.09 | $40K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 410 | 196 | $11.33 | $4,647 |
| 96372 Injection Administration | Office | 236 | 58 | $9.71 | $2,292 |
| 96413 Chemotherapy Administration | Office | 180 | 29 | $86.77 | $16K |
| 99215 Office E&M - Established | Office | 148 | 69 | $120.72 | $18K |
| 99213 Office E&M - Established | Office | 134 | 93 | $61.24 | $8,206 |
| 96365 Intravenous Infusion, Hydration | Office | 126 | 52 | $41.45 | $5,223 |
By year: 2022 $1.8M for 129,017 services; 2023 $1.4M for 152,301 services; 2024 $2.2M for 152,810 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 947 | 247 | $7.54 | $7,144 |
| 36415 Venipuncture Blood Collection | 733 | 226 | $8.61 | $6,309 |
Medicare prescription drug claims, 2024
In 2024, the drug Shailendra Lakhanpal prescribed most often to Medicare patients was Tamoxifen Citrate, with 186 prescriptions and refills. In total Shailendra Lakhanpal wrote 3,239 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamoxifen Citrate Generic | 186 | 453 | 52 | $7,579 |
| Ondansetron Hcl Generic | 168 | 171 | 75 | $1,189 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 148 | 149 | 42 | $6,058 |
| Eliquis Apixaban | 124 | 133 | 26 | $77K |
| Prednisone Generic | 109 | 149 | 26 | $510 |
| Anastrozole Generic | 94 | 208 | 26 | $2,131 |
| Dexamethasone Generic | 86 | 109 | 49 | $1,481 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 81 | 81 | 20 | $2,497 |
| Letrozole Generic | 76 | 203 | 27 | $2,391 |
| Revlimid Lenalidomide | 75 | 75 | 14 | $1.1M |
| Pantoprazole Sodium Generic | 73 | 177 | 39 | $936 |
| Valacyclovir Valacyclovir Hcl | 72 | 108 | 29 | $2,537 |
| Alprazolam Generic | 72 | 72 | 21 | $255 |
| Potassium Chloride Generic | 69 | 83 | 24 | $680 |
| Hydroxyurea Generic | 65 | 131 | 21 | $2,193 |
Brand drugs: - claims; generic drugs: 2,557 claims; opioid claims: 353.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shailendra Lakhanpal $9,059 ($6,643 in general payments such as food, travel and fees and $2,416 for research) from 39 companies. The largest payer was Avyxa Pharma, LLC with $3,151.
| Company | Payments | Amount |
|---|---|---|
| Avyxa Pharma, LLC | 6 | $3,151 |
| F. Hoffmann-La Roche AG ROG.SW | 1 | $2,416 |
| Novartis Pharmaceuticals Corporation NVS | 23 | $1,358 |
| Merck Sharp & Dohme LLC MRK | 8 | $170 |
| Janssen Biotech, Inc. JNJ | 8 | $154 |
| Abbvie Inc. ABBV | 8 | $142 |
| Celgene Corporation BMY | 9 | $141 |
| Pfizer Inc. PFE | 6 | $122 |
| Array Biopharma Inc PFE | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $101 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.